SBIR/STTR Research Award
Diadenosine Tetraphosphate Analogs--Antiplatelet Effects
Award amount
$695,770Program and phase
SBIR · Phase IIAward year
1996Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Prp, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
We will characterize three newly-developed chemical analogues of diadenosine-5',5'''-P1P4 tetraphosfor their antiplatelet potency. These new AP4A analogues will be characterized with respect to (1) iinduced platelet aggregation, (2) effect on platelet release reactions and platelet factor 3 activitregulatory factors in platelet activation, (4) effect on aggregating agents other than ADP, (5) timeinduced platelet aggregation in whole blood systems, (6) stability of the agent in whole blood, (7)different components of blood, and (8) test for aggregatability of platelets previously exposed to tdemonstration of superior in vitro antiplatelet activity in one or all of these analogues would ultiII testing. Accordingly, this Phase I studies, if successful, have a clear connection to Phase II st
Technology keywords
Not reported